B cell depletion, in the context of both MEK inhibitor plus PD1 inhibitor therapy (Fig 6B) and MEK inhibitor monotherapy (Fig 6D), resulted in faster tumor growth, indicating that B cells play a significant role in anti-tumor immunity in the context of MEK inhibition. The gene discussed is PDCD1; the disease is neoplasm.